File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1200/JCO.2025.43.16_suppl.11127
- Find via

Supplementary
-
Citations:
- Appears in Collections:
Article: Evaluating acceptance of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: Lessons from a randomized controlled trial
| Title | Evaluating acceptance of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: Lessons from a randomized controlled trial |
|---|---|
| Authors | |
| Issue Date | 28-May-2025 |
| Publisher | American Society of Clinical Oncology |
| Citation | Journal of Clinical Oncology, 2025, v. 43, n. 16_suppl How to Cite? |
| Abstract | Background: Scalp cooling is effective in preventing chemotherapy-induced alopecia (CIA) in cancer patients. However, its effect and acceptance are not certain in gynecologic cancer patients particularly in Asia. Methods: The CHARM study was a single-center randomized study. Women with proven gynecologic cancer planning for 3-weekly carboplatin and paclitaxel were randomised to receive usual care (control group) or scalp cooling using the Paxman Orbis II system (Paxman Coolers Limited, Huddersfield, United Kingdom) (intervention group). The primary endpoint was the incidence of psychological distress, i.e., Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) score ≥10. The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UWB 19-514). Results: Between November 2019 to November 2021,142 women were invited to join the study. 56 women (39.4%) declined to participate, and the most common reason was worries about coldness (Table 1). 44 women were randomized to the intervention group and 42 to the control group. Fewer women in the intervention had psychological distress compared to the control group after cycle 2 of chemotherapy (27.8% vs 62.2%, p=0.003). The incidence of Grade ≥ 3 adverse events were similar between both groups (7.5% vs 5.1%, p=1.0). However, 12 out of 40 (30.0%) in the intervention group did not comply with scalp cooling, among which nine (75%) were due to feeling cold despite measures like using blankets and hot water. Conclusions: Scalp cooling was associated lesspsychological distress in Asian women using chemotherapy for gynecologic cancer. Nevertheless, the high refusal rate to join the study and high drop-out rate limited its use in these women. This might be partially due to some misbelief that associated head coldness with poor general health in Traditional Chinese Medicine. More strategies are needed to improve the acceptance of scalp cooling. |
| Persistent Identifier | http://hdl.handle.net/10722/359257 |
| ISSN | 2023 Impact Factor: 42.1 2023 SCImago Journal Rankings: 10.639 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tse, KY | - |
| dc.contributor.author | Kwok, GST | - |
| dc.contributor.author | Lau, LSK | - |
| dc.contributor.author | Chan, TO | - |
| dc.contributor.author | Chu, MMY | - |
| dc.contributor.author | Ngu, SF | - |
| dc.contributor.author | Chan, KKL | - |
| dc.contributor.author | Ngan, HYS | - |
| dc.contributor.author | Ho, PPY | - |
| dc.contributor.author | Wu, L | - |
| dc.contributor.author | Hung, DSM | - |
| dc.contributor.author | Lo, HKY | - |
| dc.contributor.author | Wong, CSM | - |
| dc.date.accessioned | 2025-08-26T00:30:29Z | - |
| dc.date.available | 2025-08-26T00:30:29Z | - |
| dc.date.issued | 2025-05-28 | - |
| dc.identifier.citation | Journal of Clinical Oncology, 2025, v. 43, n. 16_suppl | - |
| dc.identifier.issn | 0732-183X | - |
| dc.identifier.uri | http://hdl.handle.net/10722/359257 | - |
| dc.description.abstract | <p><strong>Background:</strong> Scalp cooling is effective in preventing chemotherapy-induced alopecia (CIA) in cancer patients. However, its effect and acceptance are not certain in gynecologic cancer patients particularly in Asia. <br></p><p><strong>Methods:</strong> The CHARM study was a single-center randomized study. Women with proven gynecologic cancer planning for 3-weekly carboplatin and paclitaxel were randomised to receive usual care (control group) or scalp cooling using the Paxman Orbis II system (Paxman Coolers Limited, Huddersfield, United Kingdom) (intervention group). The primary endpoint was the incidence of psychological distress, i.e., Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) score ≥10. The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UWB 19-514). <br></p><p><strong>Results:</strong> Between November 2019 to November 2021,142 women were invited to join the study. 56 women (39.4%) declined to participate, and the most common reason was worries about coldness (Table 1). 44 women were randomized to the intervention group and 42 to the control group. Fewer women in the intervention had psychological distress compared to the control group after cycle 2 of chemotherapy (27.8% vs 62.2%, p=0.003). The incidence of Grade ≥ 3 adverse events were similar between both groups (7.5% vs 5.1%, p=1.0). However, 12 out of 40 (30.0%) in the intervention group did not comply with scalp cooling, among which nine (75%) were due to feeling cold despite measures like using blankets and hot water. <br></p><p><strong>Conclusions:</strong> Scalp cooling was associated lesspsychological distress in Asian women using chemotherapy for gynecologic cancer. Nevertheless, the high refusal rate to join the study and high drop-out rate limited its use in these women. This might be partially due to some misbelief that associated head coldness with poor general health in Traditional Chinese Medicine. More strategies are needed to improve the acceptance of scalp cooling.</p> | - |
| dc.language | eng | - |
| dc.publisher | American Society of Clinical Oncology | - |
| dc.relation.ispartof | Journal of Clinical Oncology | - |
| dc.title | Evaluating acceptance of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: Lessons from a randomized controlled trial | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1200/JCO.2025.43.16_suppl.11127 | - |
| dc.identifier.volume | 43 | - |
| dc.identifier.issue | 16_suppl | - |
| dc.identifier.eissn | 1527-7755 | - |
| dc.identifier.issnl | 0732-183X | - |
